• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

作者信息

Bartalena Luigi, Baldeschi Lelio, Dickinson Alison, Eckstein Anja, Kendall-Taylor Pat, Marcocci Claudio, Mourits Maarten, Perros Petros, Boboridis Kostas, Boschi Antonella, Currò Nicola, Daumerie Chantal, Kahaly George J, Krassas Gerasimos E, Lane Carol M, Lazarus John H, Marinò Michele, Nardi Marco, Neoh Christopher, Orgiazzi Jacques, Pearce Simon, Pinchera Aldo, Pitz Susanne, Salvi Mario, Sivelli Paolo, Stahl Matthias, von Arx Georg, Wiersinga Wilmar M

机构信息

Department of Clinical Medicine, University of Insubria, 21100 Varese, Italy.

出版信息

Eur J Endocrinol. 2008 Mar;158(3):273-85. doi: 10.1530/EJE-07-0666.

DOI:10.1530/EJE-07-0666
PMID:18299459
Abstract
摘要

相似文献

1
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.欧洲Graves眼病专家组（EUGOGO）关于Graves眼病管理的共识声明。
Eur J Endocrinol. 2008 Mar;158(3):273-85. doi: 10.1530/EJE-07-0666.
2
Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy.欧洲Graves眼病专家组（EUGOGO）关于Graves眼病管理的共识声明。
Thyroid. 2008 Mar;18(3):333-46. doi: 10.1089/thy.2007.0315.
3
Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.格雷夫斯眼眶病在欧洲作为一种罕见疾病：欧洲格雷夫斯眼眶病研究小组（EUGOGO）立场声明
Orphanet J Rare Dis. 2017 Apr 20;12(1):72. doi: 10.1186/s13023-017-0625-1.
4
[Management of Graves' orbitopathy: evidence-based recommendations].[格雷夫斯眼眶病的管理：循证推荐意见]
Dtsch Med Wochenschr. 2009 Dec;134(49):2521-4. doi: 10.1055/s-0029-1243057. Epub 2009 Nov 25.
5
The EUGOGO consensus statement on the management of Graves' orbitopathy: equally applicable to North American clinicians and patients.欧洲Graves眼病专家组（EUGOGO）关于Graves眼病管理的共识声明：同样适用于北美临床医生和患者。
Thyroid. 2008 Mar;18(3):281-2. doi: 10.1089/thy.2008.0034.
6
[Management of Graves' orbitopathy. Comments on the EUGOGO consensus statement].[格雷夫斯眼眶病的管理。对EUGOGO共识声明的评论]
Endokrynol Pol. 2009 Jul-Aug;60(4):312-30.
7
PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.PREGO（格雷夫斯眼眶病表现）研究：2000年至2012年期间转诊至欧洲格雷夫斯眼眶病研究组（EUGOGO）中心的模式变化。
Br J Ophthalmol. 2015 Nov;99(11):1531-5. doi: 10.1136/bjophthalmol-2015-306733. Epub 2015 May 7.
8
Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).2012 年至 2019 年（PREGO III）期间欧洲 Graves 眼病研究组（EUGOGO）中心的 Graves 眼病表现。
Br J Ophthalmol. 2024 Jan 29;108(2):294-300. doi: 10.1136/bjo-2022-322442.
9
THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy.内分泌疾病的治疗：内分泌难题：格雷夫斯眼眶病的管理
Eur J Endocrinol. 2016 Sep;175(3):R117-33. doi: 10.1530/EJE-15-1164. Epub 2016 Mar 31.
10
Management of patients with Graves' orbitopathy: initial assessment, management outside specialized centres and referral pathways.格雷夫斯眼眶病患者的管理：初始评估、非专科中心的管理及转诊途径
Clin Endocrinol (Oxf). 2016 May;84(5):662-3. doi: 10.1111/cen.13039. Epub 2016 Mar 2.

引用本文的文献

1
Bibliometrics in thyroid eye disease.甲状腺眼病的文献计量学
J Endocrinol Invest. 2025 Aug 29. doi: 10.1007/s40618-025-02688-0.
2
Exploring thyroid eye disease in Brazil: insights from a single-center study.探索巴西的甲状腺眼病：一项单中心研究的见解
Arch Endocrinol Metab. 2025 Aug 20;69(3):e240495. doi: 10.20945/2359-4292-2024-0495.
3
Efficacy and safety of various Intravenous Methylprednisolone regimens in Moderate to Severe Thyroid Eye Disease: A systematic review.不同静脉注射甲泼尼龙方案治疗中重度甲状腺眼病的疗效与安全性：一项系统评价
Indian J Ophthalmol. 2025 Aug 1;73(8):1100-1107. doi: 10.4103/IJO.IJO_1808_24. Epub 2025 Jul 28.
4
Effects of pulse glucocorticoid treatment on retinal blood flow in patients with active Graves' orbitopathy.脉冲糖皮质激素治疗对活动性格雷夫斯眼病患者视网膜血流的影响。
BMC Ophthalmol. 2025 Jul 1;25(1):361. doi: 10.1186/s12886-025-04184-8.
5
Lamina cribrosa curvature depth and index as novel parameters in Graves' ophthalmopathy.筛板曲率深度和指数作为Graves眼病的新参数
Sci Rep. 2025 Jul 2;15(1):22981. doi: 10.1038/s41598-025-06584-8.
6
Deep learning system for the auxiliary diagnosis of thyroid eye disease: evaluation of ocular inflammation, eyelid retraction, and eye movement disorder.用于甲状腺眼病辅助诊断的深度学习系统：眼部炎症、眼睑退缩和眼球运动障碍的评估
Front Cell Dev Biol. 2025 Jun 16;13:1609231. doi: 10.3389/fcell.2025.1609231. eCollection 2025.
7
The burden of illness in thyroid eye disease: current state of the evidence.甲状腺眼病的疾病负担：证据现状
Front Ophthalmol (Lausanne). 2025 Apr 17;5:1565762. doi: 10.3389/fopht.2025.1565762. eCollection 2025.
8
Thyroid-related orbitopathy: clinical overview, novel medical treatments and the role of orbital surgery.甲状腺相关眼病：临床概述、新型药物治疗及眼眶手术的作用
Int Ophthalmol. 2025 May 3;45(1):160. doi: 10.1007/s10792-025-03535-0.
9
Meibomian Gland Loss and Dysfunction in Mild versus Moderate-Severe Thyroid Eye Disease.轻度与中重度甲状腺眼病中的睑板腺缺失和功能障碍
J Curr Ophthalmol. 2025 Jan 18;36(2):145-151. doi: 10.4103/joco.joco_176_23. eCollection 2024 Apr-Jun.
10
Study on the correlation between serum IgG4/IgG levels and the development of Graves' ophthalmopathy.血清IgG4/IgG水平与Graves眼病发生发展的相关性研究
Sci Rep. 2025 Jan 22;15(1):2770. doi: 10.1038/s41598-025-87126-0.